Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Farnier

Showing results (21-30 of 144) with videos related to

Pageof 15
Sort By:
Timely Topics in Medicine. Cardiovascular Diseases|December 13, 2005
New strategies in the treatment of hypercholesterolemiaJohn Kastelein, Michel Farnier
Archives of Cardiovascular Diseases|December 4, 2012
Severe familial hypercholesterolaemia: current and future managementMichel Farnier, Eric Bruckert
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|February 25, 2009
Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterolAlberto Corsini, Eberhard Windler, Michel Farnier
The American Journal of Cardiology|September 7, 2010
Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapyMichel Farnier, Jean Ducobu, Leszek Bryniarski
Presse Medicale (Paris, France : 1983)|March 12, 2019
[PCSK9 inhibitors: What place in the management of dyslipidemia?]Pierre Sabouret, Michel Farnier, Etienne Puymirat
Current Medical Research and Opinion|October 7, 2011
Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapyMichel Farnier, Jean Ducobu, Leszek Bryniarski
Archives of Cardiovascular Diseases|September 27, 2025
Optimizing oral low-density lipoprotein cholesterol-lowering therapy in statin-intolerant patients: A simulation study in FranceFrancois Schiele, Michel Farnier, Bénédicte Borsik
Atherosclerosis. Supplements|April 25, 2017
How to implement clinical guidelines to optimise familial hypercholesterolaemia diagnosis and treatmentMichel Farnier, Fernando Civeira, Olivier Descamps, et al.
Diabetes & Vascular Disease Research|January 10, 2012
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular diseaseMichel Farnier, Kjetil Retterstøl, Armin Steinmetz, et al.
Clinical Therapeutics|March 15, 2011
Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative studyMichel Farnier, Armin Steinmetz, Kjetil Retterstøl, et al.
Pageof 15

Showing results (21-30 of 144) with videos related to

Sort By:
Pageof 15
Timely Topics in Medicine. Cardiovascular Diseases|December 13, 2005
New strategies in the treatment of hypercholesterolemiaJohn Kastelein, Michel Farnier
Archives of Cardiovascular Diseases|December 4, 2012
Severe familial hypercholesterolaemia: current and future managementMichel Farnier, Eric Bruckert
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|February 25, 2009
Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterolAlberto Corsini, Eberhard Windler, Michel Farnier
The American Journal of Cardiology|September 7, 2010
Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapyMichel Farnier, Jean Ducobu, Leszek Bryniarski
Presse Medicale (Paris, France : 1983)|March 12, 2019
[PCSK9 inhibitors: What place in the management of dyslipidemia?]Pierre Sabouret, Michel Farnier, Etienne Puymirat
Current Medical Research and Opinion|October 7, 2011
Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapyMichel Farnier, Jean Ducobu, Leszek Bryniarski
Archives of Cardiovascular Diseases|September 27, 2025
Optimizing oral low-density lipoprotein cholesterol-lowering therapy in statin-intolerant patients: A simulation study in FranceFrancois Schiele, Michel Farnier, Bénédicte Borsik
Atherosclerosis. Supplements|April 25, 2017
How to implement clinical guidelines to optimise familial hypercholesterolaemia diagnosis and treatmentMichel Farnier, Fernando Civeira, Olivier Descamps, et al.
Diabetes & Vascular Disease Research|January 10, 2012
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular diseaseMichel Farnier, Kjetil Retterstøl, Armin Steinmetz, et al.
Clinical Therapeutics|March 15, 2011
Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative studyMichel Farnier, Armin Steinmetz, Kjetil Retterstøl, et al.
Pageof 15